Stock Analiz

Neonc Technologies Holdings, Inc. NTHI

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$4.91Market cap $142M
Open the interactive analysis →

Neonc Technologies Holdings, Inc. (NTHI) is a healthcare company listed in the US with a market value of about $142M. In fiscal year 2025 it had revenue of $39990 and net income of -$62M, a net margin of -155404.4%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

About Neonc Technologies

Neonc Technologies is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 2 years in our data. It spends 9098% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-14.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-51.8%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-84867.8%
ROIC (5-yr avg.)—
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 2 years

Fiscal year20252024
Revenue$39990$83000
Net income-$62M-$12M
Free cash flow-$21M—
EPS (diluted)$-3.20$-0.69
Net margin-155400.0%-14335.5%
ROIC——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $17.00, 246% above the current price; targets range from $13.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.24 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Neonc Technologies pay a dividend?

Not currently.

Is Neonc Technologies a good stock to buy?

We do not give buy or sell advice. Neonc Technologies scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.